ES8603949A1 - Procedimiento para la produccion de factor de necrosis tumoral humana (htnf) purificado - Google Patents

Procedimiento para la produccion de factor de necrosis tumoral humana (htnf) purificado

Info

Publication number
ES8603949A1
ES8603949A1 ES533767A ES533767A ES8603949A1 ES 8603949 A1 ES8603949 A1 ES 8603949A1 ES 533767 A ES533767 A ES 533767A ES 533767 A ES533767 A ES 533767A ES 8603949 A1 ES8603949 A1 ES 8603949A1
Authority
ES
Spain
Prior art keywords
human
htnf
necrosis factor
conjunction
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES533767A
Other languages
English (en)
Other versions
ES533767A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of ES8603949A1 publication Critical patent/ES8603949A1/es
Publication of ES533767A0 publication Critical patent/ES533767A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROCEDIMIENTO PARA LA PRODUCCION DE FACTOR DE NECROSIS TUMORAL HUMANA (HTNF) PURIFICADO. COMPRENDE: A) INCUBAR CELULAS HEMATOPOIETICAS HUMANAS INICIALMENTE EN CULTIVO DE TEJIDO, EN MEDIO RPMI 1640 CONTENIENDO FCS EN UNA CANTIDAD DE 0 A 8%, A UNA TEMPERATURA DE 37JC DURANTE 48 HORAS; B) SEPARAR LA PARTE SOBRENADANTE DEL CULTIVO CELULAR DE DICHAS CELULAS POR CENTRIFUGADO; C) RECOGER DICHAS CELULAS; D) RESUSPENDER LAS CELULAS; E) REINCUBAR LAS CELULAS EN MEDIO RPMI 1640, A UNA TEMPERATURA DE 37JC Y DURANTE 48 HORAS; F) RECOGER LA PARTE SOBRENADANTE CELULAR; Y G) CONGELAR LA PARTE SOBRENADANTE SIN LAS CELULAS. LAS CELULAS HEMATOPOIETICAS SON CELULAS B HUMANAS. SE UTILIZA EL (HTNF) PARA EL TRATAMIENTO DEL CANCER.
ES533767A 1983-06-27 1984-06-27 Procedimiento para la produccion de factor de necrosis tumoral humana (htnf) purificado Granted ES533767A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50847283A 1983-06-27 1983-06-27

Publications (2)

Publication Number Publication Date
ES8603949A1 true ES8603949A1 (es) 1986-01-01
ES533767A0 ES533767A0 (es) 1986-01-01

Family

ID=24022900

Family Applications (2)

Application Number Title Priority Date Filing Date
ES533767A Granted ES533767A0 (es) 1983-06-27 1984-06-27 Procedimiento para la produccion de factor de necrosis tumoral humana (htnf) purificado
ES545258A Expired ES8608885A1 (es) 1983-06-27 1985-07-16 Procedimiento para distinguir celulas normales de malignas, en una mezcla de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES545258A Expired ES8608885A1 (es) 1983-06-27 1985-07-16 Procedimiento para distinguir celulas normales de malignas, en una mezcla de las mismas

Country Status (15)

Country Link
EP (1) EP0131789A3 (es)
JP (1) JPS6036420A (es)
KR (1) KR850000528A (es)
AU (1) AU587959B2 (es)
CA (1) CA1265444A (es)
DD (3) DD229713A5 (es)
DK (1) DK311984A (es)
ES (2) ES533767A0 (es)
FI (1) FI842560A (es)
GR (1) GR82260B (es)
HU (2) HU197358B (es)
NO (1) NO842572L (es)
NZ (1) NZ208648A (es)
PT (1) PT78773B (es)
ZA (1) ZA844377B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
JPS59141519A (ja) * 1983-01-31 1984-08-14 Otsuka Pharmaceut Co Ltd 制ガン作用を有する蛋白質
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
JPS60243018A (ja) * 1984-05-17 1985-12-03 Yamanouchi Pharmaceut Co Ltd ヒト内来性癌制御因子
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US6686455B1 (en) 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
GR851626B (es) * 1984-07-05 1985-11-26 Genentech Inc
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JP2557053B2 (ja) * 1984-12-21 1996-11-27 バイオジェン インコーポレイテッド 腫瘍壊死因子の精製、製造および使用法
EP0205038A1 (en) * 1985-05-29 1986-12-17 Suntory Limited Polypeptide, process for preparing it, microorganism and pharmaceutical use
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
DE102012024749A1 (de) 2012-12-11 2014-06-26 Martin Röcken Tumorprävention und -therapie durch Induktion einer Tumorseneszenz

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
GR851626B (es) * 1984-07-05 1985-11-26 Genentech Inc

Also Published As

Publication number Publication date
AU2933784A (en) 1985-01-03
ES533767A0 (es) 1986-01-01
AU587959B2 (en) 1989-09-07
FI842560A (fi) 1984-12-28
DD241271A5 (de) 1986-12-03
DK311984D0 (da) 1984-06-26
EP0131789A2 (en) 1985-01-23
FI842560A0 (fi) 1984-06-26
JPS6036420A (ja) 1985-02-25
HUT34775A (en) 1985-04-28
DK311984A (da) 1984-12-28
EP0131789A3 (en) 1986-12-03
DD241268A5 (de) 1986-12-03
ES8608885A1 (es) 1986-07-16
DD229713A5 (de) 1985-11-13
PT78773A (en) 1984-07-01
GR82260B (es) 1984-12-13
KR850000528A (ko) 1985-02-27
NO842572L (no) 1984-12-28
ES545258A0 (es) 1986-07-16
CA1265444A (en) 1990-02-06
ZA844377B (en) 1985-05-29
PT78773B (en) 1986-06-26
HU201680B (en) 1990-12-28
NZ208648A (en) 1989-07-27
HU197358B (en) 1989-03-28

Similar Documents

Publication Publication Date Title
ES8608885A1 (es) Procedimiento para distinguir celulas normales de malignas, en una mezcla de las mismas
HUT38125A (en) Process for preparing lymphokines /cytotoxic factors/ and pharmaceutical compositions containing such active substance
MY101887A (en) A novel human physiologically active polypeptide.
MD1443F1 (en) Copolymer-1 fraction, process for preparation thereof and compositions on base thereof for cerebrospinal sclerosis treatment
AU638982B2 (en) Use of cytokines
NZ225675A (en) Treating lung conditions with gamma interferon and/or tumour necrosis factor
ES2010561A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
AU6466790A (en) Use of a polypeptide having the activity of human interleukine 2 for the preparation of pharmaceutical compositions intended for the treatment of leukemias
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
DK0452598T3 (da) Anvendelsen af et polypeptid med humant-inter-leukin-2-aktivitet til fremstilling af farmaceutiske præparater til behandling af primitiv pleuracancer
IL82143A0 (en) Pharmaceutical compositions containing interleukin-2 and/or interferon-beta and tumor necrosis factor
HUT63575A (en) Stabilized pharmaceutical composition comprising the reduced form of non-glycosylated, recombinant human interleukin-2
IL89496A0 (en) Eglin mutants,their preparation and pharmaceutical compositions containing them
MD566C2 (ro) Procedeu de preparare a materialului plastic sclerosuspendator din ţesutul osos
AU645042B2 (en) Use of a polypeptide having the activity of gamma interferon for the preparation of pharmaceutical compositions intended for the treatment of primary cancers of the pleura
Shim et al. Study on the Natural Healing Mechanism in Tumors
IL72197A0 (en) Purified human tumor necrosis factor,methods for the production thereof,pharmaceutical compositions containing the same and methods for the use thereof